Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

Trial Details

NCT ID
NCT07816666
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Torvutatug samrotecan
  • Bevacizumab
Locations (sample)
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Miami, Florida, United States|25.77427,-80.19366
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Shreveport, Louisiana, United States|32.52515,-93.75018
  • Columbia, Maryland, United States|39.24038,-76.83942

Key Eligibility Criteria

  • Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
  • Provision of an archival FFPE tumour sample
  • Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
  • Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →